Posted on 26/10/2009 in Scientific BD has revealed that it has signed a contract to acquire HandyLab, a company that specialises in the development and manufacturing of molecular diagnostic assays and automation platforms.
The acquisition is subject to regulatory approvals and is expected to close during the first quarter of the 2010 financial year.
So far, none of the monetary details of the agreement have been disclosed.
Some of BD's future plans include the placing of its BD GeneOhm molecular assays for Methicillin-resistant Staphylococcus aureus, Clostridium difficile and Vancomycin-resistant Enterococcus on to the HandyLab platform and marketing of them as the new BD MAX system.
"We believe this new platform enables both our healthcare-associated infections offering and future expansion into other molecular opportunities," commented Vincent Forlenza, president of BD.
This news follows BD's opening of a new research centre in August - a facility through which it aims to train in excess of 300 clinicians and provide a hub for improving the monitoring and treatment of individuals living with HIV and AIDS.Other news stories from 26/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
